EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Holy Stone Healthcare Co., Ltd. (4194) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Holy Stone Healthcare Co., Ltd. TWD 0.87, price TWD 7.23, upside -88.0%, quality 43 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · TW · ISIN TW0004194006

HS Thin data Sep 24, 2026

Holy Stone Healthcare Co., Ltd.

4194 · TWO

Weakest SetupStrongly overvalued and low quality.

!Fair value 0.8700 TWD · Strongly overvalued (−88%)
!Quality 43/100
!Weak Growth (revenue 5y −10.3 %/yr)
!negative free cash flow
✓Ranks above peers (5/8)
!Narrow moat 15/100
!Evidence only low, so the estimate is less certain
Watch Holy Stone Healthcare Co., Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

46.48 TWD 5.70 TWD Fair Value 0.8700 TWD Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 5.70 TWD – 46.48 TWD · fair‑value band 0.5800 TWD – 1.09 TWD · the 7.23 TWD price screens above the 0.8700 TWD fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Holy Stone Healthcare Co. in your weekly email

Every Wednesday you see whether Holy Stone Healthcare Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Holy Stone Healthcare Co., Ltd., together with its subsidiaries, develops and sells hyaluronic acid-related therapeutic products in Taiwan.

Show more

Holy Stone Healthcare Co., Ltd., together with its subsidiaries, develops and sells hyaluronic acid-related therapeutic products in Taiwan. The company offers RenehaVis and SportVis, which are injectable medical devices for osteoarthritis and soft tissue injuries; TRUD, a medical device that contains a mixture of hyaluronic acid used for the treatment and prevention of ulcerative colitis in inflammatory bowel disease (IBD); and GAF, a gel for anal fissure healing. It also develops IBD98-M, an oral capsule that is in a Phase IIa trial for ulcerative colitis; CA102N, a receptor-targeted chemotherapy that is in a Phase II trial for metastatic colorectal cancer, as well as in a pre-clinical stage for pancreatic ductal adenocarcinoma and a discovery stage for triple-negative breast cancer; ND108E, a CNS-targeted HA conjugate that is in a pre-clinical trial for Alzheimer's disease; AMD112, a non-invasive HA-conjugated small molecule therapy that is in a pre-clinical trial for wet age-related macular degeneration and other neovascular retinal diseases; and HylCaryo, a hyaluronic acid (HA)-derived nanoparticle platform in a discovery stage. In addition, the company engages in general investment; development and sale of medical devices; biotechnology services; and patent application for pharmaceutical products. Holy Stone Healthcare Co., Ltd. was founded in 2001 and is headquartered in Taipei, Taiwan.

Stock analysis

Holy Stone Healthcare Co., Ltd. (4194) currently trades at 7.23 TWD, while our model-based Fair Value estimate is 0.8700 TWD, implying the stock looks roughly 731.3% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 0.5800 TWD (bear) to 1.09 TWD (bull), the price of 7.23 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Holy Stone Healthcare Co., Ltd. reported revenue of 0 TWD in FY2025 versus 217M TWD in FY2021. Reported net income was −111M TWD in FY2025.

Key figures

Market cap 1.1B TWD (≈ $33.1M) · P/S ratio 20.6 · EPS (TTM) −0.7600 TWD · Return on equity −46.7% · Return on assets (EBIT) −67.8% · Revenue (TTM) 47.5M TWD · Free cash flow −116M TWD · Net cash 252M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 36 out of 100 (medium confidence).

What moves the price

The share trades about 32% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −88%, 4194 screens richer than that median.

Fair Value models

Bear 0.5800 TWD Fair Value 0.8700 TWD Bull 1.09 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 0.6300 TWD 0.8400 TWD 1.25 TWD 51
All 1 models by family
Asset-Based
NCAV (Graham) 0.6300 TWD 0.8400 TWD 1.25 TWD 51

Open the full fair value analysis →

Notify me when 4194 reaches fair value

Put 4194 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 43/100

Of which business quality 45 · Market factors (momentum, volatility) 33

Profitability 0
Margins and returns on capital today
Quality Growth 22
Are margins and returns improving?
Cashflow 32
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 54
Calm price path (market factor)
Momentum 30
Price trend over the last 3–12 months (market factor)
52W Momentum 12
Distance to the 52-week high (market factor)
Net Issuance 31
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−49.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−18.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−91.8% (2019) → −159.8% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

4194 screens 731% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Holy Stone Healthcare Co., Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 649 stocks

Beats the industry median on 5/7 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 45 · Above median
Fair Value upside −88% · Bottom 25%
Profitability
Return on assets −32% · Bottom 25%
Operating margin (TTM) 0% · Above median
Growth and dividend
Revenue growth 0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.18× · Cheapest 25%
P/S (TTM) 0.70× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $516.34 $567.97 +10%
Regeneron Pharmaceuticals, Inc REGN $801.82 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.12 A$197.03 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Holy Stone Healthcare Co., Ltd. · Fair Value
0.8700 TWD −731%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Holy Stone Healthcare Co., Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/4194

Frequently asked questions

Is Holy Stone Healthcare Co., Ltd. (4194) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 0.8700 TWD versus a price of 7.23 TWD, about −88% upside (overvalued).
What is the fair value of 4194?
Our model-based fair value for Holy Stone Healthcare Co., Ltd. is 0.8700 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 7.23 TWD.
What is the quality score of 4194?
Holy Stone Healthcare Co., Ltd. has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Holy Stone Healthcare Co., Ltd. (4194)?
Our model-based price target is the fair value of 0.8700 TWD (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 0.5800 TWD, optimistic scenario 1.09 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Holy Stone Healthcare Co., Ltd. stock forecast for 2026?
Our models put fair value at 0.8700 TWD, about −88% upside versus a price of 7.23 TWD (overvalued). Cautious scenario 0.5800 TWD, optimistic scenario 1.09 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Holy Stone Healthcare Co., Ltd. (4194)?
Holy Stone Healthcare Co., Ltd. reported trailing-twelve-month revenue of about 47.5M TWD (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Holy Stone Healthcare Co., Ltd. (4194)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Holy Stone Healthcare Co., Ltd. it is 0.8700 TWD per share (as of Sep 24, 2026), against a price of 7.23 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Holy Stone Healthcare Co., Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 4194 trades above its calculated fair value: price 7.23 TWD, fair value 0.8700 TWD, a gap of about −88% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4194?
No. The price is what the market pays today (7.23 TWD); the fair value is what the company's own numbers justify (0.8700 TWD). For Holy Stone Healthcare Co., Ltd. the two are 6.36 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Holy Stone Healthcare Co., Ltd. worth?
The market values Holy Stone Healthcare Co., Ltd. at about 1.1B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 7.23 TWD; our models calculate a fair value of 0.8700 TWD per share.
What do the bullish and bearish scenarios say about 4194?
Our models span a range for Holy Stone Healthcare Co., Ltd.: cautious scenario 0.5800 TWD, base 0.8700 TWD, optimistic 1.09 TWD per share (as of Sep 24, 2026, price 7.23 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Holy Stone Healthcare Co., Ltd. (4194)?
Balance-sheet figures for Holy Stone Healthcare Co., Ltd. (as of Sep 24, 2026): return on equity −46.7%. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 4194 from its 52-week high?
Holy Stone Healthcare Co., Ltd. trades at 7.23 TWD, about 32% below its 52-week high of 10.65 TWD and 20% above the low of 6.02 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 0.8700 TWD is for.
Which stocks are comparable to Holy Stone Healthcare Co., Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Holy Stone Healthcare Co., Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price 7.23 TWD, calculated fair value 0.8700 TWD (−88%), Quality Score 43/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4194 calculated?
We run Holy Stone Healthcare Co., Ltd. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.8700 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Holy Stone Healthcare Co., Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Holy Stone Healthcare Co., Ltd. (4194)?
The closing price on Sep 24, 2026 was 7.23 TWD. Our model-based fair value is 0.8700 TWD, about −88% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Holy Stone Healthcare Co., Ltd. right now?
The price sits above even our optimistic bull case (1.09 TWD). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (0.5800 TWD to 1.09 TWD) leaves room in how you read the outcome.

Key figures of Holy Stone Healthcare Co., Ltd.

How large is the market capitalisation of Holy Stone Healthcare Co., Ltd. (4194)?
The market capitalisation of Holy Stone Healthcare Co., Ltd. is 1.1B TWD (≈ $33.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Holy Stone Healthcare Co., Ltd. (4194)?
The price-to-sales ratio of Holy Stone Healthcare Co., Ltd. is 20.6 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Holy Stone Healthcare Co., Ltd. (4194)?
Earnings per share at Holy Stone Healthcare Co., Ltd. are −0.7600 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Holy Stone Healthcare Co., Ltd. (4194)?
The return on equity (ROE) of Holy Stone Healthcare Co., Ltd. is −46.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Holy Stone Healthcare Co., Ltd. (4194)?
On an EBIT basis the return on assets of Holy Stone Healthcare Co., Ltd. is −67.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Holy Stone Healthcare Co., Ltd. (4194) generate?
The free cash flow of Holy Stone Healthcare Co., Ltd. is −116M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Holy Stone Healthcare Co., Ltd. (4194) hold?
Holy Stone Healthcare Co., Ltd. holds more cash than debt, 252M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Holy Stone Healthcare Co., Ltd. in the live analysis

One click puts Holy Stone Healthcare Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.